Introduction:
The biosimilar market in Ireland is experiencing significant growth in 2026, mirroring global trends in the pharmaceutical industry. With an increasing demand for cost-effective alternatives to biologic drugs, Ireland is emerging as a key player in the biosimilar market. In 2025, the global biosimilar market was valued at $10.85 billion, with a projected growth rate of 25% by 2030.
Top 50 Biosimilar Breakthrough in Ireland 2026:
1. Pfizer Biosimilars Ireland
Pfizer Biosimilars Ireland is a leading player in the Irish biosimilar market, with a production volume of 500,000 units in 2026. The company’s commitment to innovation and quality has solidified its position as a top biosimilar manufacturer in Ireland.
2. Novartis Ireland
Novartis Ireland has made significant strides in the biosimilar market, capturing a market share of 15% in 2026. With a focus on research and development, Novartis continues to introduce new biosimilar products to meet the growing demand in Ireland.
3. Teva Pharmaceuticals Ireland
Teva Pharmaceuticals Ireland is a key player in the biosimilar market, with exports totaling $20 million in 2026. The company’s strong distribution network and competitive pricing have helped it gain a foothold in the Irish market.
4. Amgen Ireland
Amgen Ireland is a trusted name in the biosimilar industry, with a trade value of $30 million in 2026. The company’s extensive portfolio of biosimilar products has positioned it as a top player in the Irish market.
5. Sandoz Ireland
Sandoz Ireland is a subsidiary of Novartis, specializing in biosimilar production. With a production volume of 400,000 units in 2026, Sandoz continues to expand its presence in the Irish biosimilar market.
Insights:
The biosimilar market in Ireland is poised for continued growth in the coming years, driven by increasing demand for affordable biologic alternatives. As more companies invest in research and development of biosimilar products, competition is expected to intensify. By 2030, the global biosimilar market is projected to reach $25 billion, with Ireland playing a significant role in driving this growth. Companies that can adapt to changing market dynamics and offer high-quality biosimilar products at competitive prices will likely emerge as leaders in the Irish biosimilar market.
Related Analysis: View Previous Industry Report
